A Randomized, Placebo-controlled, Parallel Group, Patient-blind, Phase I Study Assessing the Safety and Exploring the Immunogenicity/Therapeutic Activity of AFFITOPE PD01A and PD03A in Patients With Early Multiple System Atrophy
Phase of Trial: Phase I
Latest Information Update: 08 Jun 2017
At a glance
- Drugs Affitope PD01 (Primary) ; Affitope PD03 (Primary)
- Indications Multiple system atrophy
- Focus Adverse reactions
- Sponsors AFFiRiS
- 07 Jun 2017 According to an AFFiRiS media release, this study is part of SYMPATH research project.
- 02 Jun 2017 Status changed from active, no longer recruiting to completed.
- 07 Sep 2016 According to an AFFiRiS media release, results of this study is expected in Q4 2017.